Women’s Health Dx
SERA PROGNOSTICS TO PRESENT AT THE BTIG VIRTUAL MEDTECH, DIGITAL HEALTH, LIFE SCIENCE & DIAGNOSTIC TOOLS CONFERENCE
Sera Prognostics, Inc., a leading health diagnostics company dedicated to improving the lives of women and babies through individualized prenatal care, will be presenting at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference. Read More >
AMERICAN MEDICAL ASSOCIATION (AMA) GRANTS SERA PROGNOSTICS A CPT® PLA CODE FOR PreTRM®, THE ONLY BROADLY VALIDATED BLOOD TEST TO ASSESS RISK OF PRETERM BIRTH
February 3, 2021- Receipt of dedicated CPT® code marks important commercialization milestone to pursue reimbursement for the PreTRM® Test. Read More >
Sera Prognostics Partners With Anthem and HealthCore to Improve Outcomes for Preterm Babies
January 05, 2021- Patient enrollment began in November for this rigorous prospective, randomized, controlled PRIME intervention trial to demonstrate the value of implementing the PreTRM® prevention strategy to improve neonatal outcomes and lower cost of care. Read More >
WHO WE ARE
PROVIDING INDIVIDUALIZED RISK ASSESSMENT TO PREDICT AND MANAGE PREMATURE BIRTH, PREECLAMPSIA, AND OTHER PREGNANCY COMPLICATIONS
Sera Prognostics is dedicated to improve the lives of women and babies through individualized prenatal care. Sera’s strategy is to deliver pivotal information to physicians to improve health and to improve the economics of healthcare delivery for pregnant women. Our first test, the PreTRM® Test, focuses on the early prediction of preterm birth risk, one of the most serious pregnancy complications which affects almost one in ten pregnancies in the U.S. alone.
Early and accurate prediction of risk for pregnancy complications helps pregnant women and their doctors better understand risks and proactively address risks of adverse pregnancy outcomes. Learn about the PreTRM® Test for Risk Management.